Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guangzhou
Clinical trial register · China

Clinical Trials in Guangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 09 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University444 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University184 Nanfang Hospital, Southern Medical University138 AstraZeneca136 Guangdong Provincial People's Hospital82
Site location
Beijing5576 Shanghai3879 Guangzhou3345 Hangzhou1819 Wuhan1343
All 625 locations
Target enrolment
to

Trials with a site in Guangzhou

3345 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Active, closed
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT04699188KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung
DrugsTNO155·Opnurasib·Tislelizumab
Novartis Pharmaceuticals
Phase 1/2
344
Guangzhou, Beijing
2021-02-24
Active, closed
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
NCT04279847Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, Myeloproliferative Neoplasm
DrugRuxolitinib
Incyte Corporation
Phase 1
140
Beijing, Guangzhou, Hangzhou, Zhengzhou
2021-02-23
Active, closed
Hoffmann-La Roche
Phase 3
270
Beijing, Guangzhou, Harbin, Shanghai, Tianjin, Wuhan, Zhejiang, Zhengzhou
2021-02-23
Active, closed
Bioverativ, a Sanofi company
Phase 3
261
Beijing, Guangzhou, Hangzhou, Jinan, Kunming, Lanzhou, Suzhou
2021-02-23
Active, closed
Mirati Therapeutics Inc.
Phase 3
453
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Liuzhou, Harbin, Xinxiang
2021-02-23
Recruiting
Sun Yat-sen University
Not applicable
320
Guangzhou
2021-02-20
Active, closed
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
NCT04619004Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 2
277
Beijing, Changchun, Chengdu, Guangzhou, Hangzhou, Harbin, Nanjing, Shanghai
2021-02-02
Recruiting
Nanjing Medical University
Not applicable
500
Beijing, Guangzhou, Nanjing, Chengdu
2021-02-01
Recruiting
Janssen Research & Development, LLC
Phase 2
510
Beijing, Guangzhou, Hangzhou, Suzhou, Tianjin, Xi'an
2021-02-01
Recruiting
Lymphadenectomy in Early Ovarian Cancer
NCT04710797Ovarian Cancer, Lymphadenectomy
Sun Yat-sen University
Not applicable
656
Guangzhou
2021-01-31
Active, closed
Jilin University
Not applicable
350
Changchun, Beijing, Chongqing, Guangzhou, Shanghai, Shenyang
2021-01-27
Active, closed
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
51
Guangzhou, Guanzhou
2021-01-23
Active, closed
Novartis Pharmaceuticals
Phase 2
69
Hefei, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Changsha, Nanjing
2021-01-20
Recruiting
Efficacy and Safety of Fecal Microbiota Transplantation
NCT04706611Fecal Microbiota Transplantation
Guangzhou First People's Hospital
Not applicable
300
Guangzhou
2021-01-15
Active, closed
Merck Sharp & Dohme LLC
Phase 3
990
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Harbin, Wuhan
2021-01-10
Active, closed
Amgen
Phase 1/2
181
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Suzhou, Qingdao, Xi’an
2021-01-04
Active, closed
Sun Yat-sen University
Phase 2
30
Guangzhou
2021-01-01
Recruiting
Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors
NCT04842812Liver Cancer, Lung Cancer, Breast Cancer, Colo-rectal Cancer
Second Affiliated Hospital of Guangzhou Medical University
Phase 1
40
Guangzhou
2021-01-01
Recruiting
Postoperative Hypoxemia Increases the Risk of Anastomotic Leak After Radical Esophagectomy
NCT07309991Esophageal Carcinoma, Esophageal Adenocarcinoma, Esophagectomy, PaO2
Sun Yat-sen University
Observational
2,500
Guangzhou, Shantou, Shijiazhuang, Shanghai, Chengdu, Nanchong
2021-01-01
Recruiting
Second Affiliated Hospital of Guangzhou Medical University
Phase 2
100
Guangzhou
2021-01-01
Recruiting
Nanjing Medical University
Not applicable
300
Guangzhou, Nanjing, Qingdao, Chengdu, Beijing
2021-01-01
Recruiting
Nanfang Hospital, Southern Medical University
Observational
280
Guangzhou
2021-01-01
Recruiting
Sixth Affiliated Hospital, Sun Yat-sen University
Not applicable
47
Guangzhou
2021-01-01
Active, closed
Hangzhou Endonom Medtech Co., Ltd.
Not applicable
120
Beijing, Changsha, Chengdu, Foshan, Fuzhou, Guangzhou, Hangzhou, Hefei
2020-12-25
Recruiting
Juventas Cell Therapy Ltd.
Phase 2
100
Beijing, Chongqing, Guangzhou, Sanhe, Zhengzhou, Wuhan, Xuzhou, Shanghai
2020-12-24
Recruiting
Combination of DPMAS and Low Volume PE for Patients With HBV Related ACLF
NCT04597164Hepatitis B, Chronic, Acute-On-Chronic Liver Failure
Third Affiliated Hospital, Sun Yat-Sen University
Observational
200
Guangzhou
2020-12-22
Recruiting
Secukinumab Open Label Roll-over Extension Protocol
NCT04638647Autoimmunity, Inflammation
DrugSecukinumab
Novartis Pharmaceuticals
Phase 4
1,000
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Shantou, Shenzhen, Wuhan
2020-12-22
Active, closed
Pfizer
Phase 3
841
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Wuhan, Changsha, Nanjing
2020-12-21
Recruiting
The Role of Skin Microecology in Diabetic Skin Lesions
NCT04916457Diabetic Foot, Diabetic Dermopathy
Nanfang Hospital, Southern Medical University
Observational
200
Guangzhou
2020-12-18
Active, closed
AstraZeneca
Phase 3
358
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Kunming, Nanchang
2020-12-16
Active, closed
Janssen Research & Development, LLC
Phase 3
518
Beijing, Changchun, Changsha, Changsha Shi, Chengdu, Chongqing, Guangzhou, Hangzhou
2020-12-07
Active, closed
Daiichi Sankyo
Phase 3
1,600
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin
2020-12-04
Recruiting
Mirati Therapeutics Inc.
Phase 2/3
626
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shenzhen
2020-12-02
Recruiting
Sun Yat-sen University
Phase 2
80
Guangzhou
2020-12-01
Active, closed
Postoperative Thrombosis Prevention in Patients With CD
NCT04486859Cushing Disease, DVT, Pulmonary Embolism
Huashan Hospital
Not applicable
206
Fuzhou, Guangzhou, Wuhan, Shanghai, Chengdu, Ürümqi, Beijing
2020-12-01
By invitation
Guangzhou Women and Children's Medical Center
Observational
100
Guangzhou
2020-12-01
Active, closed
Sun Yat-sen University
Phase 2
42
Guangzhou
2020-12-01
Active, closed
Hoffmann-La Roche
Phase 2
303
Changchun, Guangzhou, Linyi, Nanchang, Shanghai, Tianjin, Wuhan, Xi'an
2020-11-27
Active, closed
Gilead Sciences
Phase 3
331
Beijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan
2020-11-23
Recruiting
Sun Yat-sen University
Phase 2
43
Guangzhou
2020-11-17
Recruiting
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
NCT04606446Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer
DrugsPrifetrastat·Atirmociclib·Palbociclib·Letrozole
Pfizer
Phase 2
320
Beijing, Guangzhou, Changchun, Xi'an
2020-11-16
Active, closed
AstraZeneca
Phase 1/2
702
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Harbin, Jining
2020-11-12
Active, closed
Guangzhou Medical University
Observational
30
Guangzhou
2020-11-06
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
47
Hefei, Beijing, Chongqing, Guangzhou, Changsha, Shanghai, Tianjin, Hangzhou
2020-11-04
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
281
Beijing, Guangzhou, Hangzhou, Shanghai, Suzhou, Wenzhou, Wuhan
2020-11-03
Recruiting
Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs
NCT04770207Hepatocellular Carcinoma, Solid Tumor, Adult
Second Affiliated Hospital of Guangzhou Medical University
Phase 2
100
Guangzhou
2020-11-01
Recruiting
Sun Yat-sen University
Phase 3
500
Guangzhou
2020-11-01
Recruiting
Juventas Cell Therapy Ltd.
Phase 2
60
Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Jinan, Shanghai, Chengdu
2020-10-26
Recruiting
Toripalimab Combined With CAV/IE Regimen
NCT04589741Soft Tissue Sarcoma
DrugToripalimab
Sun Yat-sen University
Phase 2
134
Guangzhou
2020-10-23
Active, closed
Gilead Sciences
Phase 2
80
Beijing, Shenyang, Hangzhou, Changchun, Changsha, Chengdu, Chongqing, Guangzhou
2020-10-23
Active, closed
Bayer
Phase 3
774
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Shenzhen
2020-10-20
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
516
Guangzhou
2020-10-14
Active, closed
Janssen Research & Development, LLC
Phase 3
308
Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou
2020-10-13
Active, closed
Hoffmann-La Roche
Phase 3
992
Anyang, Baoding, Beijing, Bengbu, Changchun, Changsha, Fujian, Guangzhou
2020-10-09
Active, closed
Hoffmann-La Roche
Phase 3
210
Beijing, Guangzhou, Hangzhou, Nanjing, Nantong, Shanghai, Wuhan
2020-10-08
Active, closed
Acerta Pharma BV
Phase 3
611
Beijing, Changchun, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Luoyang
2020-10-08
Active, closed
GlaxoSmithKline
Phase 3
302
Beijing, Changchun, Changsha, Guangzhou, Hangzhou, Jiangsu, Nanchang, Shenyang
2020-10-01
Active, closed
Janssen Research & Development, LLC
Phase 3
1,074
Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Guangzhou, Hangzhou
2020-09-30
Active, closed
AbbVie
Phase 3
527
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Changsha
2020-09-30
Recruiting
Ascentage Pharma Group Inc.
Phase 1/2
682
Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Changsha, Suzhou, Shanghai
2020-09-28
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1/2
310
Hefei, Beijing, Guangzhou, Zhuhai, Guangdong, Shijiazhuang, Harbin, Luoyang
2020-09-27
Active, closed
Daiichi Sankyo Co., Ltd.
Phase 3
40
Beijing, Guangzhou, Hangzhou, Shanghai
2020-09-25
Active, closed
Janssen Research & Development, LLC
Phase 3
696
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing, Ningbo
2020-09-23
Active, closed
argenx
Phase 2
229
Beijing, Changsha, Chengdu, Chifeng, Fuzhou, Guangzhou, Guanzhou, Guiyang
2020-09-18
Active, closed
Janssen Research & Development, LLC
Phase 2
194
Beijing, Chengdu, Guangzhou, Hangzhou, Shanghai, Shenyang, Tianjin, Xi'an
2020-09-17
Active, closed
ADC Therapeutics S.A.
Phase 3
440
Beijing, Xiamen, Guangzhou, Zhengzhou, Changchun, Dalian, Shanghai, Chengdu
2020-09-16
Recruiting
Epygenix
Phase 3
150
Beijing, Chongqing, Guangzhou, Shenzhen, Guiyang, Wuhan, Changsha, Xuzhou
2020-09-15
Active, closed
AbbVie
Phase 3
531
Beijing, Lanzhou, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Nanjing, Suzhou
2020-09-10
Active, closed
A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.
NCT05395533CD20-positive B-cell Non-Hodgkin Lymphoma
DrugTRS005
Zhejiang Teruisi Pharmaceutical Inc.
Phase 1
147
Beijing, Guangzhou, Zhengzhou, Suzhou, Tianjin
2020-09-08
Recruiting
Evaluate the Safety and Clinical Activity of HH2853
NCT04390737FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor
DrugHH2853
Haihe Biopharma Co., Ltd.
Phase 1/2
254
Hefei, Beijing, Guangzhou, Nanning, Zhengzhou, Wuhan, Changsha, Nanjing
2020-09-08
Active, closed
Yanhong Deng
Phase 3
528
Guangzhou
2020-09-01
Recruiting
Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma
NCT04453826Nasopharyngeal Cancer, Chemotherapy, Radiotherapy, PD-1 Therapy
DrugCamrelizumab
Sun Yat-sen University
Phase 3
388
Guangzhou, Shaoguan, Zhongshan, Zhuhai, Wuzhou
2020-09-01
Recruiting
Ascentage Pharma Group Inc.
Phase 1/2
123
Beijing, Chongqing, Guangzhou, Nanning, Guiyang, Shijiazhuang, Zhenzhou, Wuhan
2020-08-31
Recruiting
Thrombus Aspiration in STEMI Patients With High Thrombus Burden
NCT04212494ST-segment Elevation Myocardial Infarction (STEMI)
Guangdong Provincial People's Hospital
Not applicable
3,838
Fuzhou, Foshan, Guangzhou, Huizhou, Jiangmen, Kaiping, Maoming, Shantou
2020-08-30
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
125
Beijing, Guangzhou, Hangzhou, Wenzhou, Wuhan
2020-08-25
Active, closed
PharmaEssentia
Phase 3
174
Beijing, Chongqing, Guangzhou, Wuhan, Suzhou, Shenyang, Xi'an, Jinan
2020-08-25
Active, closed
Sun Yat-sen University
Not applicable
1,124
Chongqing, Lanzhou, Guangzhou, Shenzhen, Guilin, Zhengzhou, Wuhan, Nanjing
2020-08-25
Recruiting
Sun Yat-sen University
Phase 3
508
Guangzhou, Shaoguan, Zhongshan, Wuzhou
2020-08-18
Active, closed
Sun Yat-sen University
Phase 3
381
Guangzhou
2020-08-17
Recruiting
A Prospective Cohort Study of Metabolic Associated Fatty Liver Disease in China
NCT04573283Metabolic Associated Fatty Liver Disease
Nanfang Hospital, Southern Medical University
Observational
3,000
Guangzhou
2020-08-17
Active, closed
Transcenta Therapeutics (Hangzhou) Co., Ltd.
Phase 1/2
320
Bengbu, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Guangxi, Haikou
2020-08-13
Recruiting
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Phase 3
352
Guangzhou
2020-08-01
Active, closed
ASPIrin in Reducing Events in Dialysis ( ASPIRED )
NCT04381143CKD (Chronic Kidney Disease) Stage 5D
DrugAspirin
Guangdong Provincial People's Hospital
Phase 4
9,082
Fuzhou, Longyan, Lanzhou, Dongguan, Foshan, Guangzhou, Guanzhou, Heyuan
2020-07-30
Active, closed
AstraZeneca
Phase 3
866
Baoding, Beijing, Changchun, Changsha, Dalian, Foshan, Fuzhou, Guangzhou
2020-07-24
Active, closed
GlaxoSmithKline
Phase 3
242
Beijing, Changchun, Chongqing, Guangzhou, Nanchang, Nanjing, Shanghai, Tianjin
2020-07-14
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
537
Beijing, Guangzhou, Zhengzhou, Nanjing, Shanghai, Chengdu, Hangzhou
2020-07-14
Active, closed
AstraZeneca
Phase 3
1,012
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang
2020-07-13
Recruiting
Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma
NCT04453813Nasopharyngeal Carcinoma, Chemotherapy, Radiotherapy, PD-1 Treatment
DrugToripalimab
Sun Yat-sen University
Phase 3
226
Guangzhou, Shaoguan, Zhongshan, Zhuhai, Wuzhou
2020-07-03
Recruiting
Sun Yat-sen University
Not applicable
500
Guangzhou, Zhuhai, Nanchang
2020-06-30
Active, closed
Actelion
Phase 3
935
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Shanghai, Shenyang, Tianjin
2020-06-30
Recruiting
Assisting Pulmonary Disease Diagnosis With Ophthalmic Artificial Intelligence Technology
NCT05847894Pulmonary Diseases, Ophthalmological Diagnostic Techniques, Artificial Intelligence
Zhongshan Ophthalmic Center, Sun Yat-sen University
Observational
10,000
Guangzhou, Shenzhen
2020-06-29
Active, closed
Eli Lilly and Company
Phase 3
996
Hefei, Chongqing, Xiamen, Foshan, Guangzhou, Wuhan, Changsha, Changzhou
2020-06-22
Recruiting
First Affiliated Hospital, Sun Yat-Sen University
Observational
1,000
Guangzhou, Macao
2020-06-20
Recruiting
Third Affiliated Hospital, Sun Yat-Sen University
Not applicable
200
Guangzhou
2020-06-04
Active, closed
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Phase 2
76
Guangzhou
2020-06-03
Active, closed
AstraZeneca
Phase 2
452
Chengdu, Guangzhou, Hefei, Shanghai, Shenyang, Wuhan, Zhengzhou
2020-06-03
Recruiting
Sixth Affiliated Hospital, Sun Yat-sen University
Observational
300
Guangzhou
2020-06-01
Active, closed
BeiGene
Phase 3
453
Hefei, Beijing, Fuzhou, Quanzhou, Xiamen, Guangzhou, Jiangmen, Shantou
2020-05-29
Recruiting
Third Affiliated Hospital, Sun Yat-Sen University
Observational
300
Guangzhou
2020-05-15
Active, closed
AstraZeneca
Phase 3
805
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Guangdong, Guangzhou
2020-05-05
Recruiting
Sun Yat-sen University
Phase 3
207
Guangzhou
2020-05-03
Recruiting
Guangdong Provincial People's Hospital
Observational
600
Guangzhou, Guanzhou
2020-05-01
Recruiting
Chinese Obesity and MEtabolic Surgery Database (COMES Database)
NCT06275061Obesity, Metabolic Surgery, Bariatric Surgery, Weight Loss
Jinan University Guangzhou
Observational
1,000,000
Guangzhou
2020-05-01
Active, closed
Xynomic Pharmaceuticals, Inc.
Phase 2
87
Beijing, Changchun, Chengdu, Dalian, Fuzhou, Guangzhou, Hainan, Hangzhou
2020-04-22
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
60
Guangzhou, Chengdu, Hangzhou
2020-04-17
Active, closed
AstraZeneca
Phase 3
818
Baoding, Beijing, Changchun, Chongqing, Dalian, Foshan, Gongshu District, Guangzhou
2020-04-16
Active, closed
GlaxoSmithKline
Phase 3
325
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Nanchang, Shenzhen, Tianjin
2020-04-02
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
1,000
Guangzhou
2020-04-01
Recruiting
Detecting Chemosensitivity and Predicting Treatmemt Efficacy With CTCs in mNPC
NCT04544969Circulating Tumor Cell, Nasopharyngeal Carcinoma, Distant Metastases.Clinical, Effects of Chemotherapy
Sun Yat-sen University
Observational
50
Guangzhou
2020-04-01
Recruiting
Cognitive Impairment in Ageing People
NCT04360200MCI, Alzheimer Disease, VAD - Vascular Dementia, Cognitive Impairment
Yamei Tang
Observational
5,000
Guangzhou
2020-04-01
Active, closed
Astellas Pharma Global Development, Inc.
Phase 3
886
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2020-03-30
Recruiting
Yanhong Deng
Phase 3
582
Guangzhou
2020-03-27
Active, closed
Eli Lilly and Company
Phase 2
77
Beijing, Guangzhou, Changsha, Changchun, Jinan, Shanghai, Tianjin, Hangzhou
2020-03-16
Active, closed
Sun Yat-sen University
Phase 2
68
Guangzhou
2020-03-12
Recruiting
Amgen
Phase 1
479
Beijing, Guangzhou, Nanchang, Shanghai, Hangzhou, Nanjing, Wenzhou
2020-03-04
Recruiting
Sun Yat-sen University
Phase 3
212
Guangzhou, Beijing, Chengdu, Fuzhou, Guiyang, Hangzhou, Nanchang, Nanning
2020-03-01
Active, closed
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
NCT04152499Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma
DrugSacituzumab tirumotecan
Klus Pharma Inc.
Phase 1/2
1,410
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou
2020-02-28
Recruiting
Abbisko Therapeutics Co, Ltd
Phase 1
200
Bengbu, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Weifang, Haerbin
2020-02-26
Active, closed
Eli Lilly and Company
Phase 3
261
Beijing, Guangzhou, Harbin, Wuhan, Changsha, Changzhou, Changchun, Shanghai
2020-02-17
Active, closed
Loxo Oncology, Inc.
Phase 3
291
Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Harbin, Zhengzhou
2020-02-11
Active, closed
AbbVie
Phase 3
56
Beijing, Guangzhou, Shenzhen, Shenyang, Shanghai
2020-02-04
Active, closed
Sun Yat-sen University
Phase 2
246
Guangzhou
2020-01-31
Active, closed
Hoffmann-La Roche
Phase 2/3
325
Beijing, Changchun, Chongqing, Fujian, Guangzhou, Hangzhou, Harbin, Shanghai
2020-01-29
Recruiting
Xynomic Pharmaceuticals, Inc.
Phase 2
170
Beijing, Chengdu, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Lanzhou
2020-01-20
Active, closed
AstraZeneca
Phase 3
155
Beijing, Changchun, Changsha, Changzhou, Guangzhou, Guiyang, Hangzhou, Hefei
2020-01-20
Active, closed
BeOne Medicines
Phase 3
955
Beijing, Fuzhou, Quanzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing
2020-01-16
Active, closed
Actelion
Phase 3
138
Beijing, Guangzhou, Qingdao, Shanghai, Shenyang
2020-01-16
Recruiting
Carotid Revascularization for Radiation Induced Carotid Artery Stenosis
NCT05134246Radiation-induced Carotid Artery Stenosis
Xuanwu Hospital, Beijing
Observational
150
Beijing, Guangzhou
2020-01-05
Recruiting
Third Affiliated Hospital, Sun Yat-Sen University
Observational
45
Guangzhou
2020-01-01
Recruiting
Guangdong Provincial People's Hospital
Observational
6,500
Guangzhou
2020-01-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
168
Beijing, Guangzhou, Changsha, Hohhot, Shanghai, Xi’an, Chengdu, Hanzhou
2020-01-01
Recruiting
AI Recognition of Important Structures in Otolaryngological Surgery
NCT06726551Otolaryngological Diseases Requiring Mastoidectomy, Middle Ear Surgery, Endolymphatic Sac Surgery, Cochlear Implant, Labyrinthectomy, Petrous Apex Lesions, Facial Nerve Surgery, and Lateral Skull Base Tumors
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
1,000
Guangzhou
2020-01-01
Recruiting
Guangdong Provincial People's Hospital
Observational
6,000
Guangzhou
2020-01-01
Active, closed
Guangdong Provincial People's Hospital
Observational
224
Guangzhou
2020-01-01
Recruiting
Sun Yat-sen University
Phase 3
346
Guangzhou
2020-01-01
Recruiting
Guangdong Provincial People's Hospital
Observational
50,000
Guangzhou
2020-01-01
Recruiting
Sun Yat-sen University
Observational
700
Guangzhou
2020-01-01
Active, closed
CStone Pharmaceuticals
Phase 3
534
Bengbu, Hefei, Beijing, Fuzhou, Xiamen, Foshan, Guangzhou, Nanning
2019-12-13
Recruiting
Sun Yat-Sen University Cancer Center
Not applicable
232
Guangzhou
2019-12-11
Recruiting
Alexion Pharmaceuticals, Inc.
Observational
500
Chengdu, Beijing, Changchun, Guangzhou, Jinan, Nanchang, Qingdao, Shijiazhuang
2019-12-02
Active, closed
Regeneron Pharmaceuticals
Phase 2
515
Beijing, Tianjin, Chongqing, Guangzhou, Harbin, Zhengzhou, Wuhan, Suzhou
2019-11-13
Recruiting
Celgene
Phase 2
99
Guangzhou, Shenzhen, Nanning, Chengdu
2019-11-07
Active, closed
Novartis Pharmaceuticals
Phase 1
120
Guangzhou
2019-10-30
Recruiting
Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)
NCT03983226Ovarian Cancer Recurrent, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
DrugNiraparib
Shanghai Gynecologic Oncology Group
Phase 2
167
Shanghai, Guangzhou, Hangzhou
2019-10-18
Active, closed
Sun Yat-sen University
Phase 2
34
Guangzhou
2019-10-09
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
466
Guangzhou, Zhanjiang, Zhengzhou, Changsha, Wuhan, Nanjing, Xuzhou, Nanchang
2019-10-02
Recruiting
Nanfang Hospital, Southern Medical University
Not applicable
60
Guangzhou
2019-09-29
Active, closed
Janssen Research & Development, LLC
Phase 2/3
1,064
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Ganzhou, Guangzhou
2019-09-26
By invitation
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
NCT03683186PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension
United Therapeutics
Phase 3
1,000
Beijing, Guangzhou, Changsha, Shanghai
2019-09-23
Active, closed
Astellas (Beijing) Pharmaceutical R&D Co., Ltd.
Phase 3
180
Beijing, Changchun, Changsha, Fuzhou, Guangzhou, Hangzhou, Nanchang, Shanghai
2019-09-11
Active, closed
Janssen Research & Development, LLC
Phase 1
701
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan
2019-09-04
Active, closed
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
NCT06239155Advanced Solid Tumors, Hepatocellular Carcinoma
DrugAST-3424
Ascentawits Pharmaceuticals, Ltd
Phase 1/2
51
Guangzhou, Zhengzhou, Nanjing, Shenyang, Shanghai, Hangzhou
2019-09-03
Recruiting
Second Affiliated Hospital of Guangzhou Medical University
Early Phase 1
11
Guangzhou
2019-09-01
Recruiting
Sun Yat-sen University
Phase 2
80
Guangzhou
2019-09-01
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
540
Guangzhou
2019-08-20
Active, closed
BeOne Medicines
Phase 3
510
Beijing, Fuzhou, Quanzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha
2019-08-20
Active, closed
Janssen Research & Development, LLC
Phase 2/3
118
Beijing, Changchun, Chengdu, Guangzhou, Haikou, Hangzhou, Lanzhou, Nanjing
2019-08-15
Active, closed
Sanofi
Observational
1,860
Beijing, Changsha, Chongqing, Guangzhou, Harbin, Shanghai, Shenzhen, Suzhou
2019-08-15
Recruiting
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
NCT04064060Myelodysplastic Syndromes (MDS), Beta-thalassemia, Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis
DrugLuspatercept
Celgene
Phase 3
665
Beijing, Guangzhou, Shanghai, Chengdu, Tianjin, Hangzhou
2019-08-12
Recruiting
Bristol-Myers Squibb
Phase 2
1,500
Hefei, Beijing, Guangzhou, Harbin, Changsha, Nanjing, Changchun, Xi'an
2019-08-09
Active, closed
Guangdong Association of Clinical Trials
Phase 2
316
Guangzhou
2019-08-08
Active, closed
Bristol-Myers Squibb
Phase 3
839
Hefei, Xiamen, Zhangzhou, Lanzhou, Foshan, Guangzhou, Nanning, Harbin
2019-08-05
Recruiting
Haihe Biopharma Co., Ltd.
Phase 1/2
183
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Haikou, Harbin, Zhengzhou
2019-07-15
Active, closed
Decreasing Risk of Psychosis by Sulforaphane (DROPS Trial)
NCT03932136Clinical High Risk Syndrome of Psychosis
Shanghai Jiao Tong University School of Medicine
Phase 3
300
Guangzhou, Zhengzhou, Changsha, Suzhou, Shanghai, Shenzhen, Tianjin
2019-07-14
Active, closed
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
NCT04008797Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms
DrugsE7386·Doxorubicin·Lenvatinib·Paclitaxel
Eisai Inc.
Phase 1/2
301
Beijing, Changchun, Fuzhou, Guangzhou, Jinan, Kunming, Shanghai, Shenzhen
2019-07-11
Active, closed
Dizal Pharmaceuticals
Phase 1/2
315
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou
2019-07-09
Active, closed
Ascentage Pharma Group Inc.
Phase 1
80
Guangzhou, Zhengzhou, Changchun
2019-07-04
Active, closed
AstraZeneca
Phase 3
587
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Haikou, Hangzhou
2019-07-02
Recruiting
Beijing Hospital
Not applicable
115
Beijing, Guangzhou, Harbin, Nanjing, Xuzhou, Changchun, Xi'an, Luzhou
2019-07-02
Active, closed
AstraZeneca
Phase 3
923
Beijing, Changchun, Changsha, Chengdu, Foshan, Guangzhou, Guiyang, Haikou
2019-06-25
Active, closed
SyMap Medical (Suzhou), Ltd.
Not applicable
160
Beijing, Guangzhou, Shenzhen, Shijiazhuang, Qiqihar, Nanjing, Suzhou, Xuzhou
2019-06-18
Active, closed
Sun Yat-sen University
Observational
813
Guangzhou
2019-06-06
Recruiting
Endoscopic Anatomy of the Breast Fascia System
NCT06678776Breast Disease, Anatomy
Haiyan Li
Observational
184
Guangzhou
2019-06-01
Recruiting
LcProt: Proteomics Longitudinal Cohort Study on Lung Cancer
NCT06778512Lung, Lung Cancer, Cancer, NSCLC
The First Affiliated Hospital of Guangzhou Medical University
Observational
2,500
Guangzhou
2019-06-01
Recruiting
Tubeless NOSES Versus Laparoscopic Radical Resection for Rectosigmoid Cancers
NCT04037956Tubeless NOSES, Traditional Laparoscopic Radical Resection, Rectosigmoid Cancers
Sixth Affiliated Hospital, Sun Yat-sen University
Not applicable
458
Guangzhou
2019-06-01
Active, closed
BeiGene
Phase 3
420
Hefei, Beijing, Chongqing, Fuzhou, Quanzhou, Xiamen, Guangzhou, Harbin
2019-05-29
Active, closed
LEO Pharma
Phase 2
131
Guangzhou, Hangzhou, Shanghai, Xi'an
2019-05-29
Recruiting
APG-2449 in Patients With Advanced Solid Tumors
NCT03917043Advanced Solid Cancer, Non Small Cell Lung Cancer, Esophageal Cancer, Ovarian Cancer
DrugAPG -2449
Ascentage Pharma Group Inc.
Phase 1
165
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Hangzhou
2019-05-27
Active, closed
Celgene
Phase 1/2
438
Beijing, Guangzhou, Zhengzhou, Wuhan, Shenyang, Shanghai, Tianjin
2019-05-20
Recruiting
Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer
NCT03926338Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H), Neoadjuvant Therapy
DrugsNeoadjuvant toripalimab·Toripalimab
Sun Yat-sen University
Phase 2
270
Guangzhou
2019-05-10
Recruiting
Diagnosis and Management of Intrauterine Growth Restriction and Congenital Anomalies
NCT03398629Intrauterine Growth Restriction, Fetal Anomaly, Chromosomal Anomalies, Pregnancy
Guangzhou Women and Children's Medical Center
Observational
10,000
Guangzhou
2019-05-01
Recruiting
Guangdong Association of Clinical Trials
Observational
100
Guangzhou
2019-05-01
Not yet open
Sixth Affiliated Hospital, Sun Yat-sen University
Observational
287
Guangzhou
2019-04-30
Recruiting
Sixth Affiliated Hospital, Sun Yat-sen University
Not applicable
650
Guangzhou
2019-04-30
Active, closed
AstraZeneca
Phase 3
810
Baoding, Beijing, Bengbu, Chongqing, Foshan, Guangzhou, Hangzhou, Harbin
2019-04-16
Active, closed
GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma
NCT03840421Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Nasopharyngeal Diseases, Head and Neck Neoplasm
DrugsGemcitabine and cisplatin·Cisplatin
Sun Yat-sen University
Phase 3
468
Guangzhou
2019-04-03
Recruiting
Human Genes and Microbiota in Early Life
NCT06926166Host and Microbiome, Pregnancy Outcomes, Pregnancy Complications, Neurodevelopmental Disorders
Guangzhou Women and Children's Medical Center
Observational
20,000
Guangzhou
2019-04-01
Active, closed
Eisai Inc.
Phase 3
1,906
Beijing, Guangzhou, Shijiazhuang, Zhengzhou, Changsha, Baotou, Nanjing, Changchun
2019-03-27
Active, closed
Sun Yat-sen University
Phase 2
40
Guangzhou
2019-03-25
Active, closed
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
NCT03816163Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
DrugsZolbetuximab·Nab-paclitaxel·Gemcitabine
Astellas Pharma Global Development, Inc.
Phase 2
393
Beijing, Changchun, Chongqing, Guangdong, Guangzhou, Harbin, Hubei, Jiangsu
2019-03-15
Recruiting
First Affiliated Hospital, Sun Yat-Sen University
Not applicable
226
Guangzhou
2019-03-01
Recruiting
Sun Yat-sen University
Phase 2
36
Guangzhou
2019-03-01
Active, closed
Acerta Pharma BV
Phase 3
984
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang
2019-02-25
Recruiting
Third Affiliated Hospital, Sun Yat-Sen University
Not applicable
150
Guangzhou
2019-02-21
Active, closed
Sun Yat-sen University
Phase 3
360
Guangzhou, Jieyang, Shantou, Zhongshan, Chengdu, Shanghai
2019-02-21
Active, closed
Janssen Research & Development, LLC
Phase 3
765
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanjing, Ningbo, Shanghai
2019-01-25
Recruiting
Fecal Microbiota Transplantation for Ulcerative Colitis
NCT03804931Ulcerative Colitis, Fecal Microbiota Transplantation
Drugs5-ASA·Mesalazine·Prednisone
Guangzhou First People's Hospital
Phase 2/3
120
Guangzhou
2019-01-20
Recruiting
Sun Yat-sen University
Phase 2
35
Guangzhou, Guiyang, Wuhan, Dalian
2019-01-15
Recruiting
Shantou University Medical College
Observational
940
Fuzhou, Guangzhou, Sanya, Shantou, Zhengzhou
2019-01-10
Active, closed
AstraZeneca
Phase 3
1,407
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Guangzhou
2019-01-04
Recruiting
Induced-T Cell Like NK Cellular Immunotherapy for Cancer Lack of MHC-I
NCT03882840Anti-cancer Cell Immunotherapy, T Cell and NK Cell
Second Affiliated Hospital of Guangzhou Medical University
Phase 1/2
60
Guangzhou
2019-01-01
Active, closed
Bidirectional Cohort Study on Improvement of Quality of Life in Patients After Coronary Intervention With Kuanxiong Aerosol
NCT06480097Angina Pectoris, Kuanzhong Aerosol, Quality of Life, Cardiac Function
Nanfang Hospital, Southern Medical University
Observational
150
Guangzhou
2019-01-01
Recruiting
Guangzhou 8th People's Hospital
Observational
300
Guangzhou
2019-01-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,240
Heifei, Shanghai, Beijing, Fuzhou Fujian, Guangzhou, Shijiazhuang, Harbin, Zhengzhou
2018-12-27
Active, closed
TNT to Increase the Clinical Complete Response Rate for Distal LARC
NCT03840239Rectal Cancer, Rectal Cancer Stage II, Rectal Cancer Stage III, Chemoradiation
DrugCapecitabine, Oxaliplatin
Sun Yat-sen University
Phase 2
98
Guangzhou
2018-12-25
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,397
Beijing, Chongqing, Xiamen, Guangzhou, Shenzhen, Harbin, Zhengzhou, Wuhan
2018-12-24
Recruiting
Sixth Affiliated Hospital, Sun Yat-sen University
Not applicable
250
Guangzhou
2018-12-17
Active, closed
Novartis Pharmaceuticals
Phase 3
5,101
Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Nanjing, Suzhou, Changchun
2018-12-07
Active, closed
AstraZeneca
Phase 3
825
Beijing, Changsha, Changzhou, Chengdu, Guangzhou, Guiyang, Hangzhou, Hefei
2018-12-06
Active, closed
OBI Pharma, Inc
Phase 3
575
Beijing, Guangzhou, Nanning, Harbin, Wuhan, Changsha, Nanjing, Changchun
2018-12-05
Active, closed
AstraZeneca
Phase 3
724
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2018-11-30
Active, closed
AstraZeneca
Phase 3
407
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2018-11-27
Active, closed
Eli Lilly and Company
Phase 2/3
393
Hefei, Wuhu, Lanzhou, Guangzhou, Harbin, Luoyang, Wuhan, Changsha
2018-11-26
Recruiting
Sun Yat-sen University
Phase 3
776
Guangzhou
2018-11-16
Recruiting
Wenzhou Medical University
Not applicable
60
Guangzhou, Changsha, Wenzhou, Beijing, Shanghai
2018-11-16
Recruiting
Second Affiliated Hospital of Guangzhou Medical University
Not applicable
100
Guangzhou
2018-11-01
Recruiting
Baduanjin-eight-silken-movement With Self-efficacy Building for Patients With Chronic Heart Failure (BESMILE-HF Study)
NCT03180320Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure
Guangdong Provincial Hospital of Traditional Chinese Medicine
Not applicable
150
Guangzhou
2018-10-22
Active, closed
AbbVie
Phase 3
265
Beijing, Guangzhou, Zhengzhou, Wuhan, Nanjing, Suzhou, Nanchang, Shenyang
2018-10-22
Active, closed
AbbVie
Phase 2
270
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Baoding, Harbin, Zhengzhou
2018-10-10
Active, closed
AstraZeneca
Phase 3
1,246
Beijing, Changchun, Changsha, Chongqing, Dalian, Guangzhou, Hangzhou, Jinan
2018-09-27
Recruiting
BeiGene
Phase 2
200
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Huizhou, Meizhou, Hechi
2018-09-19
Active, closed
AbbVie
Phase 3
1,242
Hefei, Beijing, Guangzhou, Shijiazhuang, Wuhan, Changsha, Huaian, Nanjing
2018-08-28
Active, closed
3D Medicines (Sichuan) Co., Ltd.
Phase 2
188
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Luoyang, Zhengzhou
2018-08-22
Recruiting
Merck Sharp & Dohme LLC
Phase 3
3,500
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guanghzou, Guangzhou, Guiyang
2018-08-21
Active, closed
Hoffmann-La Roche
Phase 3
257
Beijing, Changchun, Chengdu, Fujian, Guangzhou, Hangzhou, Jinan, Shanghai
2018-08-16
Recruiting
Fecal Microbiota Transplantation for Irritable Bowel Syndrome
NCT03613545Irritable Bowel Syndrome, Fecal Microbiota Transplantation
DrugAntidepressants
Guangzhou First People's Hospital
Phase 2/3
120
Guangzhou
2018-08-10
Active, closed
AbbVie
Phase 3
1,533
Beijing, Guangzhou, Wuhan, Shenyang, Hangzhou, Changsha, Shanghai
2018-08-09
Recruiting
Sun Yat-sen University
Phase 3
794
Guangzhou
2018-07-25
Active, closed
AstraZeneca
Phase 3
216
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Linhai
2018-07-19
Active, closed
Eli Lilly and Company
Phase 3
1,058
Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei
2018-07-18
Recruiting
A Study of HQP1351 in Patients With GIST or Other Solid Tumors
NCT03594422Gastrointestinal Stromal Tumor (GIST), Solid Tumor, Adult
Ascentage Pharma Group Inc.
Phase 1
100
Guangzhou, Zhengzhou, Wuhan, Beijing, Shanghai
2018-07-11
Active, closed
Beijing Friendship Hospital
Observational
2,000
Beijing, Guangzhou, Wuxi, Shanghai, Hangzhou
2018-06-29
Active, closed
Exelixis
Phase 3
837
Hefei, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing
2018-06-10
Recruiting
Nanshan Elderly Cohort Study
NCT03569735Hypertension, Type 2 Diabetes Mellitus, Cardiovascular Diseases, Stroke
Sun Yat-sen University
Observational
20,000
Shenzhen, Guangzhou
2018-05-26
Recruiting
Maternal Grandmothers in the Born in Guangzhou Cohort Study
NCT03633162Hereditary Transmission, Immune Development, Childhood Obesity, Host and Microbiome
Guangzhou Women and Children's Medical Center
Observational
5,000
Guangzhou
2018-05-21
Active, closed
Third Affiliated Hospital, Sun Yat-Sen University
Phase 4
30,000
Guangzhou
2018-05-16
Active, closed
BeiGene
Phase 3
224
Hefei, Beijing, Chongqing, Guangzhou, Shantou, Nanning, Harbin, Zhengzhou
2018-05-14
Recruiting
Zhujiang Hospital
Not applicable
96
Guangzhou
2018-05-02
Recruiting
Herui Yao
Phase 3
210
Guangzhou, Shantou, Shenzhen, Zhangjiang, Zhuhai, Nanning, Changsha
2018-05-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
797
Tianjin, Beijing, Guangzhou, Changsha, Shanghai, Xi’an, Hangzhou, Ningbo
2018-04-24
Recruiting
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
NCT03460977Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL)
DrugsMevrometostat·Xtandi·Itraconazole·Enzalutamide
Pfizer
Phase 1
453
Guangzhou, Changsha, Nanjing, Chengdu, Wenzhou
2018-04-17
Active, closed
Sun Yat-sen University
Phase 2
146
Guangzhou
2018-04-15
Active, closed
Janssen Research & Development, LLC
Phase 2/3
1,409
Beijing, Changsha, Changzhou, Chengdu, Chongqing, Ganzhou, Guangzhou, Hangzhou
2018-04-13
Active, closed
AbbVie
Phase 3
1,336
Guangzhou, Shijiazhuang, Wuhan, Changsha, Nanchang, Shanghai, Chengdu, Tianjin
2018-04-09
Active, closed
Janssen Research & Development, LLC
Phase 3
629
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing
2018-03-23
Active, closed
AbbVie
Phase 3
747
Beijing, Xiamen, Guangzhou, Wuhan, Changsha, Nanjing, Nanchang, Changchun
2018-03-21
Recruiting
Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes
NCT03264352Diabetes Mellitus, Type 2, Adverse Event, Blood Pressure, Prehypertension
DrugsAllisartan Isoproxil·Amlodipine
XueQing Yu
Phase 4
11,414
Guangzhou
2018-02-01
Recruiting
Nanfang Hospital, Southern Medical University
Phase 3
482
Guangzhou
2018-01-31
Active, closed
Radiomics Subtyping to Guide Surgery vs. Maintenance Therapy After HCC Downstaging
NCT07581769Hepatocellular Carcinoma (HCC), Downstaging, Liver Resection, Lenvatinib
First Affiliated Hospital, Sun Yat-Sen University
Observational
500
Guangzhou
2018-01-01
Active, closed
Daehwa Pharmaceutical Co., Ltd.
Phase 2/3
549
Hefei, Beijing, Guangzhou, Haikou, Harbin, Zhengzhou, Nanjing, Changchun
2017-12-18
Recruiting
Ginkgo Leaf Center for Rare Disorders
Observational
1,965
Guangzhou
2017-12-15
Active, closed
Sanofi
Phase 3
475
Beijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Shenyang
2017-12-07
Active, closed
TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma
NCT03306121Nasopharyngeal Carcinoma
DrugCCRT
Sun Yat-sen University
Phase 3
322
Guangzhou
2017-11-13
Recruiting
Guangzhou 8th People's Hospital
Observational
600
Guangzhou
2017-11-01
Active, closed
Cardiovascular Disease Cohort in Guangdong Province
NCT03351907Cardiovascular Disease
Min Xia
Observational
5,000
Guangzhou
2017-11-01
Active, closed
BeiGene
Phase 3
590
Hefei, Beijing, Chongqing, Fuzhou, Quanzhou, Guangzhou, Zhengzhou, Wuhan
2017-10-31
Active, closed
AbbVie
Phase 2
66
Hefei, Beijing, Fuzhou, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha
2017-10-12
Active, closed
AstraZeneca
Phase 3
1,324
Beijing, Changchun, Changsha, Chengdu, Dalian, Fuzhou, Guangzhou, Hangzhou
2017-10-11
Recruiting
Guangzhou 8th People's Hospital
Phase 1
40
Guangzhou
2017-10-04
Recruiting
Endoscopic Nasopharyngectomy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma Patients
NCT03353467Nasopharyngeal Carcinoma, Endoscopic Surgery, Primary Napharyngeal Carcinama, Stage I Nasopharyngeal Cancer
Sun Yat-sen University
Not applicable
228
Guangzhou, Zhongshan, Nanning
2017-10-01
Active, closed
Hoffmann-La Roche
Phase 2/3
1,000
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing
2017-09-22
Active, closed
Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis
NCT03221036Moderately to Severely Active Ulcerative Colitis
DrugVedolizumab
Takeda
Phase 3
392
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Zhangzhou, Guangzhou, Meizhou
2017-08-03
Active, closed
Eli Lilly and Company
Phase 3
5,637
Beijing, Fuzhou, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing, Jinan
2017-07-12
Recruiting
GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
NCT03198546Hepatocellular Carcinoma, Immunotherapy, CAR, GPC3 Gene Inactivation
Second Affiliated Hospital of Guangzhou Medical University
Phase 1
30
Guangzhou
2017-07-01
Recruiting
iCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care or IHC-guided Theray
NCT03192501Lung Cancer, Gene Abnormality, Gene Product Sequence Variation, Cancer
Second Affiliated Hospital of Guangzhou Medical University
Observational
250
Guangzhou
2017-07-01
Recruiting
Second Affiliated Hospital of Guangzhou Medical University
Phase 1
30
Guangzhou
2017-07-01
Active, closed
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
NCT03173248Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), Leukemia, Myeloid, Acute
DrugsIvosidenib·Azacitidine
Institut de Recherches Internationales Servier
Phase 3
146
Zhengzhou, Chengdu, Beijing, Guangzhou, Hangzhou, Tianjin
2017-06-26
Active, closed
Yang Li
Phase 2
80
Guangzhou
2017-06-12
Recruiting
A Study in Radiotherapy-related Nervous System Complications
NCT03908502Nervous System Complication
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
4,000
Guangzhou
2017-06-01
Active, closed
AstraZeneca
Phase 3
1,186
Beijing, Changchun, Changsha, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei
2017-06-01
Active, closed
Pfizer
Phase 3
296
Beijing, Changchun, Shanghai, Hangzhou, Guangzhou
2017-04-27
Recruiting
Turning Point Therapeutics, Inc.
Phase 1/2
500
Beijing, Daping, Fuzhou, Xiamen, Guangzhou, Shenzhen, Harbin, Shatin
2017-03-07
Active, closed
Sun Yat-sen University
Phase 2
164
Guangzhou
2017-02-04
Active, closed
AbbVie
Phase 3
443
Fuzhou, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Nanjing, Changchun, Shanghai
2017-02-02
Active, closed
AbbVie
Phase 3
950
Guangzhou, Shiyan, Wuhan, Changsha, Nanchang, Changchun, Shenyang, Shanghai
2017-01-31
Recruiting
Yizhuo Zhang
Phase 3
300
Guangzhou
2017-01-30
Active, closed
AstraZeneca
Phase 3
669
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Haikou
2017-01-02
Active, closed
Cohort Study in South China
NCT03288805Chronic Disease
Min Xia
Observational
110,000
Guangzhou
2017-01-01
Recruiting
XinLing Liang
Observational
1,000,000
Guangzhou
2017-01
Active, closed
Eli Lilly and Company
Phase 3
463
Bengbu, Beijing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Zhengzhou
2016-12-05
Recruiting
IgA Nephropathy Biomarkers Evaluation Study (INTEREST)
NCT02954419IgA Nephropathy, Glomerular Diseases
Sun Yat-sen University
Observational
2,000
Guangzhou
2016-11
Recruiting
Shanghai University of Traditional Chinese Medicine
Observational
50,000
Shenzhen, Ganzhou, Jinan, Kunming, Beijing, Changchun, Guangzhou, Lanzhou
2016-11
Recruiting
National Eye Institute (NEI)
Observational
5,000
Guangzhou
2016-10-04
Active, closed
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
NCT02864992Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV
DrugTepotinib
EMD Serono Research & Development Institute, Inc.
Phase 2
337
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei
2016-09-13
Active, closed
Guangzhou Institute of Respiratory Disease
Observational
442
Guangzhou
2016-08-01
Active, closed
Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY)
NCT02859038Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Shanghai Gynecologic Oncology Group
Phase 3
489
Guangzhou, Shanghai, Hangzhou, Changsha
2016-08
Recruiting
MItral Regurgitation Risk Assessment and CLinical modElling
NCT06876883Mitral Insufficiency, Mitral Regurgitation (MR)
Sun Yat-sen University
Observational
2,000
Guangzhou
2016-06-15
Recruiting
Tricuspid RegurgitAtion rIsk modeL Study (TRAIL Study)
NCT06926959Tricuspid Regurgitation
Sun Yat-sen University
Observational
3,000
Guangzhou, Jieyang, Shantou, Shenzhen, Zhanjiang, Zhongshan
2016-06-15
Active, closed
Xcovery Holdings, Inc.
Phase 3
290
Hefei, Beijing, Fuzhou, Guangzhou, Shijiazhuang, Changsha, Wuhan, Nanjing
2016-06
Recruiting
Esthetic, Clinical and Radiographic Outcomes of Immediate and Delayed Implant Placement
NCT02814149Jaw, Edentulous, Partially, Acquired Absence of Single Tooth
Sun Yat-sen University
Not applicable
40
Guangzhou
2016-05
Active, closed
Sun Yat-sen University
Not applicable
15
Guangzhou
2016-05
Recruiting
Sun Yat-sen University
Observational
5,000
Guangzhou
2016-04
Active, closed
Shanghai Jiao Tong University School of Medicine
Phase 3
786
Fuding, Fuzhou, Quanzhou, Foshan, Guangzhou, Harbin, Jiangyin, Suzhou
2016-03
Recruiting
Sixth Affiliated Hospital, Sun Yat-sen University
Not applicable
240
Guangzhou
2016-02
Recruiting
Nanjing Medical University
Observational
10,000
Beijing, Chongqing, Guangzhou, Nanning, Xingyi, Harbin, Changzhou, Suqian
2016-01-01
Recruiting
Sun Yat-sen University
Phase 3
230
Guangzhou
2016-01-01
Active, closed
Sun Yat-sen University
Not applicable
1,080
Guangzhou
2015-12-31
Active, closed
Bayer
Phase 1/2
154
Beijing, Guangzhou, Tianjin
2015-12-16
Recruiting
The First Affiliated Hospital of Guangzhou Medical University
Not applicable
11,000
Guangzhou
2015-12-12
Active, closed
Novartis Pharmaceuticals
Phase 4
233
Guangzhou, Changchun, Beijing
2015-12-11
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,052
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai
2015-11-27
Active, closed
Hoffmann-La Roche
Phase 2
534
Harbin, Wuhan, Chengdu, Beijing, Guangzhou, Hangzhou, Shanghai, Shenzhen
2015-11-19
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,503
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing, Ningbo
2015-11-19
Active, closed
AstraZeneca
Phase 3
953
Beijing, Changchun, Chongqing, Guangzhou, Hangzhou, Shanghai, Ürümqi, Wuhan
2015-11-03
Active, closed
AstraZeneca
Phase 3
682
Beijing, Changchun, Dalian, Guangzhou, Hangzhou, Kunming, Nanjing, Nanning
2015-10-21
Recruiting
China Registry for Genetic / Metabolic Liver Diseases
NCT03131427Genetic/Metabolic Liver Diseases
Beijing Friendship Hospital
Observational
20,000
Beijing, Guangzhou, Shijiazhuang, Zhengzhou, Shanghai, Chengdu, Tianjin, Ürümqi
2015-06-13
Active, closed
Sun Yat-sen University
Phase 3
236
Guangzhou
2015-06
Active, closed
Sun Yat-sen University
Phase 3
738
Guangzhou
2015-01-01
Active, closed
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
NCT02135042EBV Infection, Stage II Nasopharyngeal Carcinoma AJCC v7, Stage III Nasopharyngeal Carcinoma AJCC v7, Stage IVA Nasopharyngeal Carcinoma AJCC v7
DrugsCis-platinum·CDDP·Taxol·Fluorouracil
NRG Oncology
Phase 2/3
924
Guangdong Province, Guangzhou
2014-07-01
Recruiting
REal-world Data of CARdiometabolic ProtEcTion
NCT07038083Cardiometabolic Diseases
Sun Yat-sen University
Observational
40,000
Guangzhou
2014-01-01
Recruiting
Third Affiliated Hospital, Sun Yat-Sen University
Observational
100
Guangzhou
2014-01-01
Recruiting
Peritoneal Dialysis Registration System (PERSIST)
NCT02989298ESRD, Disorders Associated With Peritoneal Dialysis
Sun Yat-sen University
Observational
10,000
Guangzhou
2013-12
Recruiting
Wise Practice of Chinese Hemodialysis (WISHES)
NCT03001921Haemolyses and Related Conditions
Sun Yat-sen University
Observational
30,000
Guangzhou
2013-12
Recruiting
Sun Yat-sen University
Observational
5,000
Guangzhou
2013-11
Active, closed
A Long-term Extension Study of PCI-32765 (Ibrutinib)
NCT01804686Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
DrugIbrutinib
Janssen Research & Development, LLC
Phase 3
539
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shanxi, Suzhou
2013-09-09
Active, closed
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
DrugOlaparib
AstraZeneca
Phase 3
327
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2013-09-03
Active, closed
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NCT01844986Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
DrugOlaparib
AstraZeneca
Phase 3
450
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2013-08-26
Recruiting
Predicting Gastric Cancer Response to Chemo With Multimodal AI Model
NCT06451393Gastric Cancer, Chemotherapy Effect
Sixth Affiliated Hospital, Sun Yat-sen University
Observational
500
Guangzhou
2013-02-01
Recruiting
Ding Ke-Feng
Observational
55,000
Hangzhou, Beijing, Chengdu, Guangzhou, Shanghai
2013-01-01
Recruiting
Sun Yat-sen University
Observational
30,000
Guangzhou
2013-01-01
Recruiting
Myocardial Protection Effect of Simvastatin Undergoing Cardiac Surgery
NCT01653223Congenital Heart Disease, Heart Valve Disease
DrugSimvastatin
Sun Yat-sen University
Not applicable
369
Guangzhou
2013-01
Recruiting
Sun Yat-sen University
Observational
10,000
Guangzhou
2012-11
Recruiting
A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment
NCT01994057Non-small Cell Lung Cancer (NSCLC), EGFR-TKI Resistant Mutation, EGFR-TKI Sensitizing Mutation, Germline Mutations
Sun Yat-sen University
Observational
1,000
Guangzhou
2012-09
Recruiting
The Born in Guangzhou Cohort Study (BIGCS)
NCT02526901Intrauterine Hyperglycemia, Pregnancy Outcomes, Neurodevelopment, Immune Development
Guangzhou Women and Children's Medical Center
Observational
30,000
Guangzhou
2012-02-01
Recruiting
Offspring Born to Mothers With Polycystic Ovary Syndrome in Guangzhou Cohort Study
NCT03742011PCOS, Offspring, Adult, Hyperandrogenism, Epigenetics
Guangzhou Women and Children's Medical Center
Observational
2,000
Guangzhou
2012-02-01
Recruiting
IVF Offspring Born in Guangzhou
NCT03650829ART, Offspring, Adult, Genetics, Host and Microbiome
Guangzhou Women and Children's Medical Center
Observational
3,000
Guangzhou
2012-02-01
Recruiting
Twins Born in Guangzhou
NCT03331133Twin Diseases, Immune Development, Childhood Obesity, Host and Microbiome
Guangzhou Women and Children's Medical Center
Observational
1,000
Guangzhou
2012-02-01
Recruiting
Preterm Birth Cohort Study in Guangzhou
NCT03668327Preterm Birth, Neurodevelopment, Immune Development, Host and Microbiome
Guangzhou Women and Children's Medical Center
Observational
5,000
Guangzhou
2012-02-01
Recruiting
GDM and Its Consequences in Mothers and Offsprings
NCT04529889Gestational Diabetes Mellitus, Pregnancy Outcome, Neurodevelopment, Immune Development
Guangzhou Women and Children's Medical Center
Observational
7,000
Guangzhou
2012-02-01
Recruiting
Guangzhou Women and Children's Medical Center
Observational
3,000
Guangzhou
2012-02-01
Recruiting
Product Surveillance Registry
NCT01524276Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders
Medtronic
Observational
100,000
Nanning, Chengdu, Beijing, Dalian, Guangzhou, Hangzhou, Harbin, Hefei
2012-01
Recruiting
A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC
NCT03303495Colorectal Neoplasms, Neoplasm Metastasis, Intestinal Neoplasms, Gastrointestinal Neoplasms
Drugs5 FU bolus·Avastin·Fluorouracil·Leucovorin
Sun Yat-sen University
Phase 3
280
Guangzhou
2011-11-14
Recruiting
Guangdong Provincial People's Hospital
Observational
500,000
Guangzhou
2011-01-01
Recruiting
Epidemiological Insights Into the Formation, Progression, and Rupture of Intracranial Aneurysms: A Retrospective, Multi-Center Hospital-Based Study in China
NCT06456814Intracranial Aneurysm, Subarachnoid Hemorrhage, Aneurysmal, Cerebral Aneurysm, Brain Aneurysm
Zhujiang Hospital
Observational
30,000
Guangzhou
2010-01-01
Recruiting
Guangzhou 8th People's Hospital
Observational
15,000
Guangzhou
2009-01-01
Active, closed
Genentech, Inc.
Phase 2
378
Beijing, Changchun, Guangzhou, Hangzhou, Harbin, Nanjing, Shanghai
2008-10-16
Recruiting
Guangdong Provincial People's Hospital
Observational
450
Guangzhou
2006-01-04
Recruiting
The New Serial Treatment of Temporomandibular Disorders
NCT00932594Temporomandibular Disorder
Sun Yat-sen University
Not applicable
4
Guangzhou
2006-01
Recruiting
Peking Union Medical College
Observational
2,000
Beijing, Chongqing, Guangzhou, Nanning, Shijiazhuang, Tianjin, Wuhan, Nanjing
2005-01
Recruiting
Pompe Disease Registry Protocol
NCT00231400Glycogen Storage Disease Type II, Pompe Disease
Genzyme, a Sanofi Company
Observational
2,000
Beijing, Guangzhou, Jinan, Shanghai
2004-09-15
Recruiting
The Chinese Pulmonary Lymphoepithelioma-like Carcinoma Collaboration Study
NCT06801977Primary Pulmonary Lymphoepithelioma-like Carcinoma
Sun Yat-sen University
Observational
10,000
Foshan, Guangzhou
2002-01-01
Recruiting
Guangdong Provincial People's Hospital
Observational
100,000
Guangzhou
2000-01-01
Recruiting
First Affiliated Hospital, Sun Yat-Sen University
Observational
5,000
Guangzhou
1996-01-01
Recruiting
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
NCT00358943Gaucher Disease, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease
Genzyme, a Sanofi Company
Observational
12,000
Beijing, Guangzhou, Hangzhou, Nanjing, Shanghai
1991-04-01
Recruiting
Medtronic
Observational
20,000
Beijing, Changsha, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei
1983-01
Rows per page Showing 3001–3345 of 3345
Previous 5 6 7
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 November 2026. https://priyalifescience.com/clinical-trials-china/city/guangzhou?page=7

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 09 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 3,345 of those studies with a site in Guangzhou.

How many clinical trials are recruiting in Guangzhou?

1,977 of the 3,345 studies on this page are recruiting new participants as of the 09 Nov 2026, 03:17 UTC sync. A further 479 have not yet opened recruitment, 820 are active but closed to new participants, and 69 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.